CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award

- Awards recognize innovative biopharmaceutical drugs and devices that have

             made a deep impact on the quality of human life -



    PALO ALTO, Calif., Aug. 14 /EMWNews/ -- CV Therapeutics,

Inc. (Nasdaq: CVTX) today announced that its chronic angina therapy

Ranexa(R) (ranolazine extended-releases tablets) has been selected as a

finalist for the prestigious Prix Galien USA 2008 award which honors the

best pharmaceutical agent and best biotechnology product of the year.

Winners will be announced on September 24, 2008 in New York.



    "Being named a finalist for the Prix Galien USA awards is a great

honor. We congratulate the dedicated employees, researchers and physicians

who make it possible for this important medicine to help patients every

day," said Louis G. Lange, M.D., Ph.D., chairman and chief executive

officer of CV Therapeutics.



    The Prix Galien USA Awards committee of 11, including seven Nobel

Laureates, recognizes the technical, scientific and clinical research

skills necessary to develop innovative medicines that improve the human

condition, and is considered the industry's highest accolade for

pharmaceutical research and development.

    About Ranexa(R)



    In the United Sates, Ranexa(R) (ranolazine extended-release tablets) is

indicated for the treatment of chronic angina in patients who have not

achieved an adequate response with other antianginal drugs. In Europe,

ranolazine is indicated as add-on therapy for the symptomatic treatment of

patients with stable angina pectoris who are inadequately controlled or

intolerant to first-line antianginal therapies.



    About CV Therapeutics



    CV Therapeutics, Inc., headquartered in Palo Alto, California, is a

biopharmaceutical company primarily focused on applying molecular

cardiology to the discovery, development and commercialization of novel,

small molecule drugs for the treatment of cardiovascular diseases. CV

Therapeutics Ltd. is the company's European subsidiary based in the United

Kingdom.



    CV Therapeutics' approved products in the United States include

Ranexa(R) (ranolazine extended-release tablets), indicated for the

treatment of chronic angina in patients who have not achieved an adequate

response with other antianginal drugs, and Lexiscan(TM) (regadenoson)

injection for use as a pharmacologic stress agent in radionuclide

myocardial perfusion imaging in patients unable to undergo adequate

exercise stress. Ranolazine is approved for use in the European Union as

add-on therapy for the symptomatic treatment of patients with stable angina

pectoris who are inadequately controlled or intolerant to first-line

antianginal therapies.



    Except for the historical information contained herein, the matters set

forth in this press release, including statements as to research and

development and commercialization of products, are forward-looking

statements within the meaning of the "safe harbor" provisions of the

Private Securities Litigation Reform Act of 1995. These forward-looking

statements are subject to risks and uncertainties that may cause actual

results to differ materially, including operating losses and fluctuations

in operating results; capital requirements; regulatory review and approval

of our products; special protocol assessment agreement; the conduct and

timing of clinical trials; commercialization of products; market acceptance

of products; product labeling; concentrated customer base; reliance on

strategic partnerships and collaborations; uncertainties in drug

development; uncertainties regarding intellectual property and other risks

detailed from time to time in CV Therapeutics' SEC reports, including its

Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. CV

Therapeutics disclaims any intent or obligation to update these

forward-looking statements.